May 2016 Cheat Sheet

Chris Powell asks about using commercially prepared plasma for lot-to-lot validations. Does this contradict CAP policy?

Dr. Tony Tang asks about incubated mixing study limits.

Any Kelley asks about monitoring UFH when switching from rivaroxaban, a common issue.

Dr. John Olson provides the CAP mixing study reference and his expert opinion on the mixing study normal plasma. He cautions that his opinion does not necessarily reflect the official CAP position.

Dr. John Olson provides comments on the use of commercial plasma for lot-to-lot validations and for developing reference intervals.

Dennis Ernst asks, "Does the Buzzy affect hemostasis results?"

Answers to the Quick Question, "How many normal subject specimens do you collect to establish a PT and PTT reference interval?"